Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming ...

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $470.37, demonstrating a +1.88% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

Some you might hold only temporarily, while others you own for decades. David Jagielski (Eli Lilly): A forever stock you can ...

The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.

A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

The Food and Drug Administration (FDA) is hoping a newly approved non-opioid pain medication could help save lives. Dr.

For the first time in more than 25 years, the U.S. Food and Drug Administration has signed off on a new type of pain reliever ...

The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...